Pears for Practice: The 3rd Annual MA Society of Addiction Medicine Risk Management Course for All Providers

Friday, June 6 & Saturday, June 7, 2014
Massachusetts Medical Society, 860 Winter Street, Waltham, MA

Friday, June 6, 2014:

8:00 AM  DSM-5 Opioid Use Disorders: Clinical Update – Hilary S. Connelly, MD, PhD
9:00 AM  The Neurobiology of Addiction: A Brief Introduction – James A. Morrill, MD
10:00 AM  Break
10:20 AM  Addiction in Pregnancy...and Beyond to Baby – Jacquelyn Stater, MD, FACOG, FASAM & Marcia Wenner VanVleet, MD, MPH
12:05 PM  Lunch
1:00 PM  Practical Pearls for Prescribing Buprenorphine for Physicians – John Brooklyn, MD
1:55PM  Medical Complications of Addictive Behaviors – Alan A. Warenberg, MD, FACP, FASAM
2:50PM  Break
3:10 PM  Marijuana Panel – Sharon Levy, MD, MPH & Other Panelists To Be Determined
4:45 PM  Adjournment
5:00 PM  MASAM Annual Meeting and Dinner – Separate Registration Required

Saturday, June 7, 2014:

8:15 AM  Pharmacotherapies For Alcohol Dependence: An Update – Robert Swift, MD, PhD
9:15 AM  Managing Stimulant and Sedative Abuse in Patients on Opioid Replacement Treatment – John A. Renner, Jr., MD
10:10 AM  Break
10:30 AM  Dual Diagnosis: Mood Disorders and Substance use Disorders – Surita Rao, MD
11:25 AM  Current Management of HIV and Hepatitis C – Catharina Armstrong, MD
12:20 PM  Lunch
1:10 PM  Case Studies – James J. O’Connell, MD, Jacquelyn Stater, MD, FACOG, FASAM & Alan A. Warenberg, MD, FACP, FASAM
2:45PM  Break
3:10 PM  Drug Testing – Joseph Musto, MD
4:05 PM  Adjournment

CME/Accreditation Statement:
The Massachusetts Medical Society designates this live activity for a maximum of 13.25 AMA PRA Category 1 Credits™. Physicians should claim only the credits commensurate with the extent of their participation in the activity. This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the Joint Sponsorship of the Massachusetts Medical Society and the Massachusetts Society of Addiction Medicine. The Massachusetts Medical Society is accredited by the Accreditation Council for Continuing Medical Education (ACME) to provide continuing medical education for physicians.

This activity meets the criteria of the Massachusetts Board of Registration in Medicine for 13.25 risk management credits.

This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 13.25 AMA PRA Category 1 Credits™ to the MOC requirement for the Lifelong Learning and Self-Assessment requirements.
Program Faculty:

Catharina Armstrong, MD
Infectious Disease Physician, Lemuell Shattuck Hospital & Newton Wellesley Hospital; Assistant Clinical Professor, Medicine, Tufts University School of Medicine

John Brooklyn, MD
Assistant Professor of Family Medicine, Medicine and Psychiatry, University of Vermont; Medical Director, Howard Center Methadone Program Burlington, VT; Medical Director, BHHS Methadone Programs in Vermont; Physician, Community Health Center, Burlington, VT

Hilary S. Conney, MD, PhD
Clinical Director, Alcohol and Drug Abuse Treatment Program; Division of Alcohol and Drug Abuse, McLean Hospital; Assistant Professor, Department of Psychiatry, Harvard Medical School

Sharon Levy, MD
Director, Adolescent Substance Abuse Program, Children's Hospital Boston; Assistant Professor of Pediatrics, Harvard Medical School

Joseph Musto, MD
Laboratory Director, Diagnostic Laboratory Medicine, Inc.

James A. Morrill, MD
Associate Physician, Massachusetts General Hospital; Primary Care Physician, MGH and Charlestown HealthCare Center

James J. O'Connell, MD
President, Boston Health Care for the Homeless Program; Assistant Professor of Medicine, Harvard Medical School; Department of Medicine, Massachusetts General Hospital

Surita Rao, MD
Chairman & Director, Behavioral Health Department, St. Francis Hospital & Medical Center, Mt. Sinai Campus, Hartford, CT

John A. Renner, Jr., MD
Professor of Psychiatry, Boston University School of Medicine; Director, Addiction Psychiatry Fellowship Program, VA Boston Healthcare System

Jacquelyn Starer, MD, FACOG, FASAM
Director, Integrated Women's Consult Service, CleanSlate Centers; Associate Director, Physician Health Services, Inc.; Associate Physician, Addiction Recovery Program, Brigham & Women's Faulkner Hospital

Robert Swift, MD, PhD
Professor of Psychiatry and Human Behavior and Associate Director, Center for Alcohol and Addiction Studies, Brown University Alpert School of Medicine

Alan A. Wartenberg MD, FACP, FASAM
Consulting Physician, DVA Medical Center, Providence RI; Affiliated Faculty Member, Brown University Center for Alcohol and Addiction Studies

Marcia Wener VanVleet, MD, MPH
Director of Newborn Service Team, Women and Infant's Hospital

Program Summary:

This program will prepare physicians to develop the knowledge, skills, and attitudes required to identify and manage substance use disorders and addiction comorbidities in their practices.

Intended Audience:

Addiction Medicine Physicians, Psychiatrists, Neurologists, Psychologists, Therapists, Marriage and Family Therapists, Addiction Counselors, Social Workers, and any health care professionals working with addiction, smoking cessation or pain management related issues.

Educational Objectives:

As a result of participating in this activity, learners will be able to:

a. Review the science, pharmacology, neurobiology, clinical presentations and medical consequences of dependence on alcohol, opioids, stimulants, and sedatives

b. Explain the current pharmacologic treatments of opioid and alcohol use disorders with an emphasis and clinical considerations of the various medications

c. Discuss the management of patients with co-existing conditions such as HIV, Hepatitis C, dual diagnosis, pregnancy and newborn effects, and homelessness, and other medical co-morbidities

d. Discuss current topics related to marijuana use including its effects on adolescents and the current controversies regarding "medical marijuana"

e. Review methods used in toxicology testing and interpretation of results in clinical practice